Intravesical immunotherapy using Bacillus Calmette-Guérin (BCG) is a localised treatment for non-muscle invasive bladder cancer (NMIBC). This approach involves the direct introduction of live, weakened bacteria into the bladder using a catheter.
BCG activates the body’s immune system to target and destroy bladder cancer cells, helping to prevent the recurrence and progression of the disease. It is considered an effective form of immunotherapy that operates primarily within the bladder, minimising systemic side effects.
Indications for Intravesical Immunotherapy with BCG
Intravesical immunotherapy with BCG is specifically indicated for several scenarios in the treatment of bladder cancer:
- Non-Muscle Invasive Bladder Cancer (NMIBC): BCG is primarily used for NMIBC, particularly for high-risk cases where there is a greater likelihood of recurrence or progression.
- After TURBT: It is commonly administered after transurethral resection of a bladder tumour (TURBT) to reduce the risk of cancer recurrence.
- Carcinoma in Situ (CIS): This high-risk form of NMIBC, which is flat and often difficult to detect, responds well to BCG therapy.
- Prophylactic Treatment: BCG can be used as a preventive treatment to delay or prevent the recurrence of bladder cancer following surgery.
Preparation for BCG Treatment
Proper preparation is essential to ensure the safety and effectiveness of intravesical immunotherapy with BCG. Here are the necessary steps patients typically follow before undergoing this treatment:
Medical Evaluation
Patients undergo a comprehensive medical evaluation to confirm the suitability of BCG therapy. This includes reviewing their medical history, current health status, and any previous treatments for bladder cancer.
Laboratory Tests
Blood tests, urine analysis, and possibly urine cultures are performed to check for underlying conditions that might affect the treatment.
Bladder Examination
A thorough bladder examination, often through cystoscopy, is conducted to ensure no active tumours or infections.
Medication Review
Patients may need to adjust or temporarily stop certain medications, especially those that could interfere with immune response or increase the risk of bleeding.
The BCG Treatment Process
The process of administering BCG treatment for bladder cancer is meticulously planned to maximise therapeutic effectiveness while minimising discomfort. Here is an outline of the typical procedure:
Catheter Insertion
The treatment begins with inserting a catheter into the bladder through the urethra. This procedure is usually done in a hospital or clinic under sterile conditions.
BCG Instillation
Once the catheter is in place, the BCG solution, which contains a live attenuated strain of the tuberculosis bacterium, is instilled into the bladder. The catheter is removed, allowing the solution to remain in the bladder.
Retention Time
Patients are usually asked to hold the solution in their bladder for about one to two hours. This retention time is crucial as it allows the BCG to come into direct contact with the bladder wall, where it exerts its immunotherapeutic effects.
Post-Instillation Instructions
After the retention period, patients are advised to urinate in order to expel the BCG solution. To minimise the risk of spreading the bacteria, it is recommended to use a bleach solution to disinfect the toilet after each use for the first few hours post-treatment.
Treatment Schedule
BCG therapy is typically given once a week for six weeks. Depending on the patient’s response, this initial course is followed by additional maintenance treatments.
Post Treatment Care and Recovery
After completing a session of BCG treatment, proper care is crucial to manage side effects and ensure the best therapeutic outcomes. Here are the key aspects of post-treatment care and recovery:
- Hydration: Patients are encouraged to drink plenty of fluids after the treatment to help flush the bladder and reduce the concentration of BCG in the urine.
- Pain Management: Over-the-counter pain relievers may address discomfort or mild pain from the catheter or the BCG solution.
- Monitoring for Side Effects: Common side effects include urinary frequency, discomfort during urination, and flu-like symptoms such as fever and fatigue. Persistent or severe symptoms should be reported.
- Follow-Up Visits: Regular follow-up appointments are essential to monitor the effectiveness of the treatment and manage any side effects. These visits may include urine tests, cystoscopy, and discussions about symptom management.
- Precautions: Patients are advised to avoid sexual activity for 48 hours after each treatment and may be instructed to use a condom for several weeks post-treatment to protect their partners, as BCG is live bacteria.
Risks and Complications
While BCG immunotherapy is generally safe and effective for treating non-muscle invasive bladder cancer, it can have potential risks and complications, which are important for patients to be aware of:
- Infection: Although rare, live bacteria in the bladder can lead to infection. Symptoms may include persistent fever, chills, and worsening urinary symptoms.
- BCG Reaction: Some patients may experience a severe reaction to BCG, characterised by intense pain, frequent urination, blood in the urine, or a prolonged high fever. This requires immediate medical attention.
- Bladder Irritation: Common side effects include cystitis-like symptoms such as urgency, frequency, and dysuria (painful urination). These symptoms usually resolve within a few days but can be uncomfortable.
- Systemic BCGosis: Very rarely, the BCG can spread beyond the bladder, leading to a systemic infection. This serious complication is more likely in patients with compromised immune systems and necessitates urgent treatment.
- Contracting Tuberculosis: There is a minimal risk of contracting tuberculosis from the BCG strain; however, it is a possibility that requires vigilant monitoring.
Conclusion
Patients considering BCG immunotherapy should be aware of its potential side effects and the importance of adherence to post-treatment guidelines. Continuous monitoring and proper management of symptoms post-treatment can significantly enhance the effectiveness and safety of this therapy.